Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis

Gunay ER

Status and phase

Completed

Phase 4

Conditions

Enthesitis

Spondyloarthritis

Anti-Tumor Necrosis Factor Drugs

Treatments

Drug: TNF Inhibitor

Study type

Interventional

Funder types

Other

Identifiers

NCT04953871

89403766-604.01.02-147611

Details and patient eligibility

About

Biological therapies should be considered in patients with high disease activity despite nonsteroid antiinflammatory drug treatment. The first option among biological therapies is anti-Tumor Necrosis Factor (anti-TNF) drugs. In recent years, anti-TNF treatments have shown that clinical and ultrasonographic enthesitis may improve as well as disease activity, quality of life and acute phase reactants. In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.

Enrollment

31 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Spondyloarthritis patients were diagnosed according to 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria

Exclusion criteria

Severe cardiovascular and respiratory diseases,
Severe liver and kidney failure,
Pregnancy and lactation,
Active infection,
Malignancy,
Demyelinating diseases,
Systemic lupus erythematosus,
History of knee, elbow, foot and ankle surgery,
Fluoroquinolone, retinoid and fluoride use,
Local corticosteroid injection at the examination sites within the six weeks before evaluation
Peripheral neuropathy